The company said it expects total revenue of between $450 million and $475 million this year, up from the $290 million to ...

ContentsInnovationNew biopolymersFashion demands betterRegulation & policyTrump’s overhaulA new EU bioeconomy ...

Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...

Most biotech firms will be forced to reevaluate foreign relationships and re-route supply chains, or hope for a federal ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

The cost of the monkeys — a proxy for the volume of clinical trials — is projected to reach Rmb150,000 ($21,000) at the start ...

Climate-resilient agriculture uses biotechnology, biofertilizers, biopesticides, genome-edited crops, and AI-driven tools to ...

A competitor's setback was Xeris Biopharma 's ( XERS +7.39%) gain on Hump Day. On news that a potential commercial threat to ...

When a biotech company announces positive Phase 3 trial results or receives FDA approval, the market reaction is often immediate and substantial. This is not just speculation. These milestones ...

An FDA decision will extend the timeline for possible approval of Inovio's lead new drug candidate, a therapy that could ...

Compare the 2026 BSc Microbiology and BSc Biotechnology. To help you choose between a career in genetic engineering and ...